AstraZeneca (LON:AZN) Given “Buy” Rating at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by Jefferies Financial Group in a note issued to investors on Friday,Digital Look reports. They currently have a £180 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 26.12% from the company’s previous close.

Several other research analysts have also weighed in on AZN. Citigroup upped their target price on shares of AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a £115 price target on shares of AstraZeneca in a research report on Thursday, June 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of £153.33.

AstraZeneca Price Performance

Shares of AZN traded up GBX 210 during trading hours on Friday, reaching £142.72. The company had a trading volume of 50,969,355 shares, compared to its average volume of 35,587,070. The firm has a 50 day simple moving average of £138.04 and a 200-day simple moving average of £141.13. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The company has a market capitalization of £221.34 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 0.86 and a beta of 0.21. AstraZeneca has a 12-month low of £101.03 and a 12-month high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.